1. Overall Evaluations of Carcinogenicity: an Updating of IARC Monographs Volumes 1 to 42.7,1987
2. European Medicines Agency. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU. Press release. https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some. Published 2018. Accessed December 1, 2020.
3. U.S. Food & Drug Administration. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. Press release. https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity. Published 2018. Accessed December 1, 2020.
4. European Medicines Agency. EMA to review ranitidine medicines following detection of NDMA. Press release. https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma. Published 2019. Accessed December 1, 2020.
5. European Medicines Agency. Suspension of ranitidine medicines in the EU. Press release. https://www.ema.europa.eu/en/news/suspension-ranitidine-medicines-eu. Published 2020. Accessed December 1, 2020.